“DNA to direct and switch off chemo” refers to a 2009 laboratory drug-delivery experiment, not a treatment that patients can use to stop chemotherapy. In the closest matching study, researchers put the chemotherapy drug cisplatin inside liposomes and attached a nucleolin aptamer—a short DNA-based targeting strand—to guide those particles toward cells. Adding a complementary DNA strand, described as an “antidote,” could control how much drug the experimental system delivered. The work did not show that DNA can neutralize chemotherapy already circulating in a person, reverse side effects, or replace an oncologist’s treatment decisions.
What the headline meant in 2009
The exact headline appeared in a Chemistry World news report on 28 July 2009. Its wording compressed two separate ideas: directing a drug-delivery vehicle toward selected cells, and reducing delivery from that vehicle when researchers added another DNA strand. Those ideas are easy to misread as a patient-controlled on/off switch. The underlying evidence is narrower. It concerns an engineered delivery system tested in experimental cell models, not a clinically demonstrated way to start, stop, or undo chemotherapy in a human body.
As an Amazon Associate I earn from qualifying purchases.
The closest matching primary study, led by Zehui Cao, used cisplatin-loaded liposomes. A liposome is a microscopic lipid-based carrier that can hold a drug. The targeting element was a nucleolin aptamer attached to the liposome surface. In the reported experiments, complementary DNA could be added to the aptamer system to regulate the extent of delivery. The abstract describes control of experimental cell delivery; it does not report patient treatment, survival, side-effect reversal, or regulatory approval.
Outdated Drivers Are Slowing You Down
One free scan finds every outdated or missing driver and matches the right update for your exact hardware.Free scan · exact hardware matchPC Slower Than It Used to Be?
A free scan shows the junk files, broken settings and background clutter dragging Windows down - then fixes them in one click.Free scan · Windows 10 & 11How the aptamer–liposome system was supposed to work
1. Put cisplatin inside a carrier
Cisplatin was the payload. Instead of exposing cells to the drug as a freely distributed molecule, the researchers enclosed it in liposomes. The carrier was intended to present a controllable package: the drug was inside, while the outer surface could be modified with a targeting molecule.
#1 Best Overall
- TOP-SELLING CONSUMER DNA TEST: From your origins in over 3,600 places around the world to the most connections to living relatives, no other DNA test kit delivers an experience as unique and interactive as AncestryDNA.
- YOUR DATA, YOUR CONTROL: We give you full control over your genetic information. You decide what to share, and with whom.
- A FEW SIMPLE STEPS: Simply activate your DNA kit online and return your saliva sample in the prepaid package to our state-of-the-art lab. Your results will be available online in roughly six weeks.
- ORIGINS AND INHERITANCE: AncestryDNA provides more precise ancestral origins with greater geographic detail. Our innovative SideView technology takes your results even further by showing your origins and matches by parental side. *Some DNA features require an Ancestry subscription.
- BUILD YOUR FAMILY TREE: Combine what you learn from your DNA results with an Ancestry subscription and gain access to millions of family trees and the world's largest collection of online family history records. *Access to record collections varies depending on subscription level.
2. Add a nucleolin aptamer for cell recognition
The liposome was conjugated to a nucleolin aptamer. An aptamer is a short nucleic-acid strand selected for its ability to bind a particular molecular target. In this design, the aptamer supplied the recognition function, while the liposome supplied the container and cisplatin supplied the cytotoxic payload. Keeping those jobs separate is important: the DNA strand was not the chemotherapy itself.
3. Use complementary DNA as a control signal
The study abstract says that complementary DNA could be added to the aptamer and used as an “antidote” to control the extent of delivery. In plain language, the extra strand was a molecular control for the engineered carrier. It did not constitute a demonstrated antidote to cisplatin in a patient. The reported result was modulation of delivery in the experimental setup, not removal of drug that had already reached healthy tissue or the bloodstream.
What “switch off” does—and does not—mean
The phrase should be read as a statement about delivery control. If the carrier has not yet completed its targeting or release process, a complementary strand may alter the interaction designed by the researchers and reduce or otherwise control delivery under the experiment’s conditions. That is the scope of the reported switch.
Rank #2
- REVIEW IMPORTANT TEST INFO: There is a lot to consider with genetic testing. Before purchasing, review important information about Genetic Health Risk*, Carrier Status*, and Pharmacogenetics** reports at 23andme. org/test-info and 23andme. org/test-info/pharmacogenetics. A portion of your purchase may be eligible for FSA/HSA reimbursement***.
- UNDERSTAND YOUR GENETIC HEALTH: Receive 160+ personalized genetic reports, including 50+ Conditions* and wellness reports. Get insights into heart health, metabolic health, mental health, and more. You choose whether to view certain reports.
- TRACK HEALTH GOALS: Health Tracks(SM) show how everyday choices may shape your health over time. Opt in to the Family Health History Tree to input and track information to share with your healthcare provider.
- PLAN AHEAD WITH 45+ CARRIER STATUS REPORTS*: Find out whether you carry a genetic variant for inherited conditions across categories like blood, lung, and hearing health, information you can bring to family planning conversations with your healthcare provider.
- LEARN HOW YOUR BODY MAY RESPOND: FDA-authorized pharmacogenetics reports show how your DNA may impact the way your body processes certain medications**, including some used in heart health and mental health care. Talk to your healthcare provider before making any medication changes.
It does not establish any of the following:
- A patient can take DNA to stop a prescribed chemotherapy infusion.
- Complementary DNA neutralizes cisplatin already active inside cells.
- Side effects such as nausea, kidney injury, nerve damage, or low blood counts can be reliably reversed.
- An oncologist’s dose, schedule, or decision can be changed safely without medical supervision.
- The carrier works selectively enough in people to avoid normal tissues.
The 2009 news wording mentions unwanted side effects, but the available study description does not turn that phrase into a clinical efficacy claim. A delivery-control mechanism in cultured cells is an early proof-of-concept, not an emergency shutoff for chemotherapy in the body.
What the study actually demonstrated
The strongest evidence supported three linked observations. First, cisplatin could be packaged in liposomes. Second, a nucleolin aptamer could be attached as the cell-targeting component. Third, adding a complementary DNA strand could control the amount or extent of delivery measured in the experimental system. Those are meaningful engineering results because they show that recognition and control can be designed into one carrier.
The evidence described does not establish clinical safety or effectiveness. No patient population, treatment response, survival outcome, approved dose, or human side-effect profile is provided. The study abstract is about experimental cell delivery. On the material available, there is no basis to call the method an approved therapy, a current standard of care, or a treatment that is clinically available.
Rank #3
- TOP-SELLING CONSUMER DNA TEST: From your origins in over 3,600+ places around the world to the most connections to living relatives, no other DNA test kit delivers an experience as unique and interactive as AncestryDNA.
- YOUR DATA, YOUR CONTROL: We give you full control over your genetic information. You decide what to share, and with whom.
- DNA + TRAITS: Ever wondered where your freckles came from, or why you hate cilantro? AncestryDNA + Traits lets you discover 75+ genetic traits, allowing you to explore how your genes might have influenced a range of appearance, sensory, performance, nutrient, and other personal characteristics.
- A FEW SIMPLE STEPS: Simply activate your DNA kit online and return your saliva sample in the prepaid package to our state-of-the-art lab. Your results will be available online in roughly six weeks.
- ORIGINS AND INHERITANCE: AncestryDNA is the only DNA test that can show your origins results, DNA matches, and traits by each side of the family, without your parents taking a DNA test.
How this approach differs from other 2009 delivery experiments
Targeted drug delivery was an active research area in 2009, but several platforms were being investigated. The studies below should not be merged into one technology or treated as a clinical comparison.
| Experimental platform | Payload | Targeting or control idea | Evidence described |
|---|---|---|---|
| Aptamer-functionalized liposome | Cisplatin | Nucleolin aptamer for cell targeting; complementary DNA used to control delivery extent | Experimental cell delivery in the Cao study; no clinical outcome established |
| Targeted minicells | siRNA or a cytotoxic drug | Targeted minicells used for sequential treatment of drug-resistant tumors | Nature Biotechnology study published 28 June 2009; a distinct delivery platform |
| pH-responsive carbon nanotubes | Doxorubicin | Folic acid as a targeting agent; lower pH used to trigger release | Biomaterials paper reporting delivery experiments in HeLa cells |
The table shows why mechanism matters. The aptamer-liposome work used complementary DNA as a delivery-control element. The minicell work explored sequential delivery of different biological or cytotoxic payloads. The carbon-nanotube work used a targeting ligand and an acidity-dependent release trigger. None of these descriptions supplies a head-to-head clinical effectiveness result, and none demonstrates that one platform could switch off chemotherapy in patients.
Why a laboratory “off switch” is difficult to translate
Targeting is not perfectly exclusive
Aptamer binding in a controlled experiment does not guarantee that a carrier will reach only cancer cells in a person. Blood flow, protein binding, immune clearance, tissue barriers, and differences among tumors can all affect where particles travel. The available description does not establish how selectively the nucleolin-targeted liposomes behaved in humans.
Rank #4
- MAP YOUR ORIGINS ACROSS 5,000+ REGIONS: Ancestry Composition breaks down your ethnicity across 5,000+ geographic regions worldwide, the most detailed ancestry breakdown of any consumer DNA service. Ancestry Timeline estimates how many generations ago your most recent ancestor from each population lived.
- FIND LIVING RELATIVES: Opt in to DNA Relatives to see up to 1,500 people in the 23andMe database who share DNA with you, from close family to distant cousins, and message them directly. Your Family Tree builds itself automatically based on your DNA.
- DISCOVER WHAT MAKES YOU UNIQUE: See how your DNA may influence physical features, sensory preferences, and habits across 30+ traits, including cilantro taste aversion to hair texture to deep sleep.
- TRACE ANCIENT MIGRATIONS: Maternal and Paternal Haplogroup reports follow your ancestors' migration paths across continents over thousands of years (paternal haplogroup requires a Y chromosome). Find out how much of your ancestry can be traced back to the Neanderthals.
- PRIVATE BY DESIGN: Your DNA data is encrypted, protected, and always under your control. Enhanced security measures are implemented to keep your information safe. Subject to 23andMe’s Terms of Service and Privacy Statement at 23andMe online.
Controlling delivery is different from removing drug
An external complementary strand can influence an engineered interaction only while that interaction remains available to influence. Once a cytotoxic drug has been released, entered cells, or damaged tissue, stopping further carrier delivery would not necessarily undo those effects. The study does not claim that complementary DNA removes cisplatin from the body or repairs injury.
Timing and dose would be critical
A real treatment would require a reliable way to deliver the control strand at the right concentration and time, ensure that it reaches the same carriers, and predict how much drug has already been released. None of those patient-use instructions is supplied by the 2009 abstract. There is also no established clinical dosing schedule or safety margin for the proposed antidote concept.
The Tool Desk
Outbyte PC Repair FREEClear out junk files and repair common Windows errorsFree Scan →Outbyte Driver Updater FREEFix the driver behind crashes, sound loss and screen glitchesFind Drivers →Manufacturing and immune safety matter
Moving from a cell experiment to a medicine requires reproducible manufacturing, stable storage, quality testing, pharmacokinetic measurements, toxicology, and phased human trials. Liposomes, aptamers, complementary strands, and cisplatin each introduce manufacturing and safety questions. The cited material does not report that this complete development pathway was achieved.
Best Value
- REVIEW IMPORTANT TEST INFO: There is a lot to consider with genetic testing. Before purchasing, review important information about Genetic Health Risk* and Carrier Status* reports at 23andme. org/test-info. A portion of your purchase may be eligible for FSA/HSA reimbursement***.
- UNDERSTAND YOUR GENETIC HEALTH: Get 10+ Condition reports* that show whether you have genetic variants associated with a higher risk of certain conditions. Includes FDA-authorized reports, and you choose whether to view certain reports.
- PLAN AHEAD WITH 45+ CARRIER STATUS REPORTS*: Discover if you carry a genetic variant for inherited conditions across categories like blood, lung, and hearing health, information you can bring to family planning conversations with your healthcare provider.
- OPTIMIZE YOUR DAILY WELLNESS: See how your genes may influence lifestyle factors like deep sleep, lactose intolerance, genetic weight, and muscle composition.
- MAP YOUR ORIGINS ACROSS 5,000+ REGIONS: Explore your Ancestry Composition, trace maternal and paternal haplogroups (paternal requires a Y chromosome), and dig into your Neanderthal Ancestry. Opt in to find up to 1,500 DNA Relatives, and your Family Tree builds itself automatically.
Historical context: why several carrier ideas appeared together
The 2009 reports reflect a broad attempt to make chemotherapy more selective. Researchers were testing carriers that could recognize a molecular feature, release a payload under a trigger, or deliver different agents in sequence. The targeted-minicell study in Nature Biotechnology, published on 28 June 2009, examined sequential treatment of drug-resistant tumors with minicells carrying siRNA or a cytotoxic drug. That is not an aptamer-liposome study, but it illustrates the period’s interest in combining targeting with more than one therapeutic payload.
The Biomaterials paper from 2009 used single-wall carbon nanotubes loaded with doxorubicin. Folic acid served as the targeting agent, and lower pH was used to trigger release. Its abstract describes experiments in HeLa cells. This pH-triggered mechanism is conceptually different from adding complementary DNA to an aptamer system, and its results cannot be used to infer that the cisplatin liposome was clinically effective.
What a reader should conclude today
If you encounter the phrase “DNA to direct and switch off chemo,” translate it into a precise statement: researchers tested whether a DNA-based targeting strand could help direct a cisplatin carrier and whether a matching DNA strand could regulate delivery in an experiment. That is a legitimate description of molecular engineering, but it is not a patient instruction.
Recommended Free Tools
For anyone receiving chemotherapy, the safe response to side effects is to contact the oncology team or follow the urgent-care instructions supplied with the regimen. Do not add, stop, or delay a chemotherapy drug or attempt to obtain a research-grade DNA reagent based on this headline. Only the treating clinicians can assess whether an infusion should be paused, a dose changed, or supportive treatment given.
Quick Recap
Key facts at a glance
- The news report dates to 28 July 2009.
- The closest matching study used cisplatin inside liposomes.
- A nucleolin aptamer was attached to the liposome as the targeting component.
- Complementary DNA was described as an “antidote” for controlling delivery extent in the experimental system.
- The evidence does not show that DNA can switch off chemotherapy already acting in a patient.
- The available sources do not establish approval, human safety, clinical effectiveness, or present-day availability.
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
